Altimmune Announces Virtual R&D Day
GAITHERSBURG, M.D. — Altimmune, Inc. (Nasdaq: ALT), a leader in the biopharmaceutical industry, is set to host an insightful virtual R&D Day where significant advancements in their therapeutic approaches will be revealed. This event is scheduled for Thursday, March 13, 2025, and will kick off at 12:00 PM Eastern Time.
Focus of the Event
The virtual event will feature knowledgeable presentations from esteemed Key Opinion Leaders (KOLs) specializing in obesity, MASH (Metabolic Dysfunction-associated Steatotic Liver Disease), and several other crucial health indications. The focus will be on the innovative peptide-based therapeutic, pemvidutide, which presents a dual mechanism of action targeting GLP-1 and glucagon receptors.
Scientific Rationale Behind Pemvidutide
Attendees will gain a comprehensive understanding of the scientific rationale supporting pemvidutide's application in various health challenges, including obesity and MASH. The discussions will elaborate on the clinical data collected thus far and the plans for its future development. Both existing and potential investors will find the updates essential, especially with the upcoming topline data readout from the IMPACT trial, a Phase 2b clinical study assessing pemvidutide for MASH, anticipated in the second quarter of the year.
How to Attend the Virtual Event
The R&D Day can be accessed through Altimmune's dedicated investor platform. Here, attendees can engage with the discussions, ask questions, and gather insights that could shape perspectives on future investment and involvement with Altimmune.
About Altimmune and its Research Focus
Altimmune is a pioneering biopharmaceutical company committed to creating next-generation peptide-based therapeutics. Currently, the company is progressing the development of pemvidutide for the treatment of obesity, MASH, and other related conditions. This innovative approach showcases Altimmune's dedication to tackling obesity and metabolic disorders that affect millions of people worldwide.
Connect with Altimmune
Stay updated with Altimmune's latest developments and breakthroughs in peptide therapies by following them on social media platforms like LinkedIn and Twitter. They actively share updates that could prove beneficial for current and future stakeholders eager to follow their journey and innovations in the biopharmaceutical landscape.
Contact Information for Inquiries
If there are questions or requests for additional information regarding the upcoming R&D Day or general inquiries about Altimmune, you can reach out to:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
Email: ir@altimmune.com
Lee Roth
Burns McClellan
Phone: 646-382-3403
Email: lroth@burnsmc.com
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Email: danielle.cantey@inizioevoke.com
Frequently Asked Questions
What is the date of Altimmune’s virtual R&D Day?
The virtual R&D Day is scheduled for March 13, 2025.
What topics will be covered during the event?
Discussions will include obesity, MASH, and the therapeutic pemvidutide, along with clinical data and future plans for development.
How can I participate in the event?
You can join the event through the dedicated investor platform hosted by Altimmune.
Who can I contact for more information?
For inquiries, you can reach out to Greg Weaver, CFO, or other contacts mentioned in the article.
What is pemvidutide used for?
Pemvidutide is a GLP-1/glucagon dual receptor agonist aimed at treating obesity and MASH, along with other indications.
